Clinical Trials Logo

Clinical Trial Summary

The specific objective of this study is to investigate the potential for normal platelets to reverse the inhibition of platelet aggregation in patients treated with ticagrelor in combination with aspirin.

Clinical Trial Description

Ticagrelor is one of three commercially available antiplatelet adenosine diphosphate (ADP) antagonists (the other two are clopidogrel and prasugrel). They exert their antiplatelet effects by binding to P2Y12 receptors on the platelet surface. Ticagrelor is used in combination with aspirin to prevent and treat thrombosis in patients with acute coronary syndrome, particularly after stent implantation. ADP antagonists are combined with aspirin because aspirin blocks platelet aggregation by preventing thromboxane production, and blocking two different pathways leads to greater efficacy than either drug used alone. Recent clinical trials indicate ticagrelor in combination with aspirin is more effective for prevention of thrombotic events in patients with symptomatic coronary artery disease than aspirin in combination with clopidogrel, but causes significantly more bleeding. The improved efficacy and reduced safety occurs because ticagrelor causes greater inhibition of ADP-mediated platelet activation. The latter can be reliably measured in the laboratory.

Management of patients who bleed while taking an ADP antagonist in combination with aspirin is challenging because there is no specific antidote, Platelet transfusion has the potential to reverse the effects of clopidogrel or prasugrel and aspirin, but these findings cannot be extrapolated to ticagrelor in combination with aspirin because the pharmacokinetic and pharmacodynamic effects of ticagrelor differ.

Aspirin, clopidogrel active metabolite, and prasugrel active metabolite have half-lives of 15-20 minutes, 30 minutes, and four hours respectively. They are irreversible platelet inhibitors which bind to and permanently block platelet function. After their drug elimination, new platelets which enter the circulation from megakaryocytes in the bone marrow are unaffected. Therefore, after elimination, newly transfused platelets have the potential to restore haemostasis. In contrast, ticagrelor, a reversible platelet inhibitor, has a longer half-life (7.7 to 14.1 hours). As a result of its longer half-life, newly added platelets (both from the bone marrow and transfused platelets) are inhibited by ticagrelor for at least 24 hours after the last dose. Therefore, reversing platelet inhibition and controlling excessive bleeding associated with ticagrelor by platelet transfusion poses a greater challenge than with clopidogrel and prasugrel. Nevertheless, because of its greater efficacy, ticagrelor is preferred over clopidogrel in high risk patients.

Previous studies of platelet transfusion and ev vivo mixing within 24 hours of drug administration have shown than the inhibition of ADP-mediated platelet activation by clopidogrel and prasugrel, but not ticagrelor can be reversed or modulated by the addition of donor platelets. Although reversing the platelet inhibitory effects of ticagrelor might not be possible within 24 hours of stopping the drug, it should be possible in the days that follow. This has not been examined. Accordingly, we propose to perform a study in which we systematically evaluate inhibition of ADP mediated platelet activation, a reliable measure of ticagrelor's antiplatelet activity, when donor platelets are added to the platelets of subjects treated with ticagrelor at time intervals up to 96 hours after their last dose. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT03005704
Study type Interventional
Source Hamilton Health Sciences Corporation
Status Recruiting
Phase N/A
Start date January 2017
Completion date January 2018

See also
  Status Clinical Trial Phase
Recruiting NCT00978159 - Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia Phase 4
Recruiting NCT04153760 - Pilot PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity Early Phase 1
Recruiting NCT03356769 - Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex Phase 2
Not yet recruiting NCT03871517 - INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE Phase 4
Completed NCT01582217 - Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition N/A
Recruiting NCT01268917 - The Effects of Preoperative Aspirin on Graft Patency and Cardiac Events in Off-pump Coronary Artery Bypass Phase 3
Recruiting NCT03450317 - Influence of Aspirin on Human Gut Microbiota Composition and Metabolome N/A
Completed NCT03424408 - Serum Thromboxane B2 Assay as a Measure of Platelet Production in Healthy Volunteers Taking Aspirin N/A
Completed NCT01900639 - Aspirin AM or PM: Effect on Circadian Rhythm of Platelet Reactivity Phase 4
Not yet recruiting NCT04912505 - ASPirin in Immune thRombocytopenia Patients With Cardiovascular disEase Phase 2
Recruiting NCT03188471 - Preventive Application of GnRH Antagonist on Early OHSS Phase 4
Recruiting NCT03785015 - When Should Low-dose Aspirin be Resumed After Peptic Ulcer Bleeding? N/A
Completed NCT00753753 - VerifyNow French Registry N/A
Recruiting NCT04356326 - Chronic Hypertension and Acetyl Salicylic Acid in Pregnancy Phase 3
Recruiting NCT04214990 - Aspirin Use for Gastric Cancer Prevention in the Early Gastric Cancer Patients Phase 3
Enrolling by invitation NCT04365309 - Protective Effect of Aspirin on COVID-19 Patients Phase 2/Phase 3
Active, not recruiting NCT03049085 - Effect of Preoperative Aspirin in Patients Undergoing Off-pump Coronary Artery Bypass Grafting Phase 4
Withdrawn NCT01058902 - The Effect Of Aspirin On Survival in Lung Cancer Phase 3
Completed NCT01669824 - Pharmacy Based Pharmacoepidemiological Observational Study With Aspirin Protect 100 mg N/A
Withdrawn NCT00363753 - Pilot Study of Continuing Aspirin Versus Switching to Clopidogrel After Stroke or Transient Ischemic Attack Phase 1